Susquehanna International Group’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-36,700
Closed -$106K 12310
2025
Q3
$106K Buy
+36,700
New +$125K ﹤0.01% 11531
2025
Q1
Sell
-19,700
Closed -$66K 12445
2024
Q4
$66K Sell
19,700
-77,600
-80% -$258K ﹤0.01% 11564
2024
Q3
$326K Sell
97,300
-82,200
-46% -$298K ﹤0.01% 9424
2024
Q2
$594K Sell
179,500
-5,000
-3% -$18.6K ﹤0.01% 7856
2024
Q1
$745K Buy
184,500
+155,100
+528% +$607K ﹤0.01% 7568
2023
Q4
$89.7K Buy
+29,400
New +$89K ﹤0.01% 11406
2023
Q3
Sell
-33,800
Closed -$126K 11992
2023
Q2
$126K Buy
+33,800
New +$127K ﹤0.01% 10745
2023
Q1
Sell
-24,500
Closed -$118K 12535
2022
Q4
$118K Sell
24,500
-17,200
-41% -$87K ﹤0.01% 10787
2022
Q3
$237K Buy
41,700
+5,900
+16% +$45.2K ﹤0.01% 10410
2022
Q2
$254K Sell
35,800
-32,900
-48% -$225K ﹤0.01% 10009
2022
Q1
$496K Sell
68,700
-3,800
-5% -$25.8K ﹤0.01% 9004
2021
Q4
$648K Sell
72,500
-17,900
-20% -$279K ﹤0.01% 8459
2021
Q3
$3.17M Buy
90,400
+19,700
+28% +$546K ﹤0.01% 4838
2021
Q2
$1.52M Buy
70,700
+63,300
+855% +$1.9M ﹤0.01% 6604
2021
Q1
$457K Buy
+7,400
New +$500K ﹤0.01% 9694

Other funds holding AVIR

Susquehanna International Group's AVIR Position: Q1 2026 in Review

Susquehanna International Group increased its Atea Pharmaceuticals (AVIR) stake by 377% in Q1 2026, buying an estimated $297K and bringing the position to 81,835 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #9987.

Susquehanna International Group first reported a position in AVIR in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.75M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Susquehanna International Group held 81,835 shares of Atea Pharmaceuticals worth $440K as of Q1 2026.
  • Susquehanna International Group bought 64,679 Atea Pharmaceuticals shares in Q1 2026, an estimated $297K.
  • Atea Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9987 holding.
  • Susquehanna International Group first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Atea Pharmaceuticals position peaked at $2.75M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.